ALZpath and Quanterix expand strategic licensing agreement. Read the full announcement →

ALZpath Logo
Contact Us

News

Media Inquiries: media@alzpath.bio

ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer’s Disease Biomarker Research

Read More

Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer’s disease assessment across primary and specialty care.

Read More

ALZpath Broadens Strategic Agreement with Alamar Biosciences to Advance Clinical Diagnostics for Alzheimer’s Disease

Read More

ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline

Read More

ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer’s Disease Testing

Read More

Broad AD/PD™ 2026 Validation Reinforces ALZpath pTau217 Antibody as Industry Benchmark for Blood-Based Alzheimer’s Diagnosis

Read More

ALZpath Commits to Eliminating the ‘D-Word’ to Reduce Stigma and Support Early Alzheimer’s Detection

Read More

ALZpath-Powered Blood Test Enables Landmark Study on Growing Alzheimer’s Disease Prevalence

Read More

ALZpath and Siemens Healthineers Sign Licensing Agreement to Advance Global Access to Blood-Based Alzheimer’s Disease Diagnostic Testing

Read More

ALZpath Proprietary pTau217 Antibody Wins BioTech Breakthrough Award for ‘Diagnostics Innovation of the Year’

Read More

Global Momentum and Validation Grows at AAIC for ALZpath Proprietary pTau217 Antibody Use in Alzheimer’s Disease Research, Diagnosis, and Treatment

Read More

ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer’s Disease Diagnostics

Read More

Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis

Read More

ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor

Read More

ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025

Read More

ALZpath Appoints Mike Banville as CEO

Read More

Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research

Read More

ALZpath Proprietary pTau217 Antibody Named to TIME’S List of the Best Inventions of 2024

Read More

New Data Presented at AAIC 2024 Demonstrates High Accuracy of Blood Tests Incorporating ALZpath Proprietary pTau217 Antibody for Alzheimer’s Disease Diagnosis

Read More

ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease

Read More

ALZpath Announces Appointment of Chad Holland as President and Chief Executive Officer

Read More

ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease

Read More

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer’s Disease Research

Read More

New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain

Read More

ALZpath Announces New Funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to Advance a Novel, Diagnostic Blood-Based Assay

Read More

ALZpath Inc., an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated and Scalable Assay for Detection of Phosphorylated Tau 217 in Blood

Read More